James Mulay Purchases Shares of CG Oncology

On June 15, 2026, insider James Mulay purchased 1,964 shares of CG Oncology, Inc. (NasdaqGS:CGON). The shares were bought at an average price of $9.64 each, totaling approximately $18,925.69. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at CG Oncology, Inc.

James Mulay was active on June 15, acquiring 1,964 shares at $9.64 each. This was a direct purchase, indicating his interest in increasing his holdings. On the same day, he also executed planned sales at a higher price of $60.12. Other insiders, such as Christina Rossi and Victor Edward Jr., were also active, each buying 9,354 shares on June 4.

Other Institutional Activity in CG Oncology

Several institutional investors have recently adjusted their positions in CG Oncology. RTW Investments, LP significantly increased its stake by 4,972,681 shares, bringing its total to 6,984,808 shares valued at about $472.73 million. T. Rowe Price Investment Management, Inc. also boosted its holdings by 6,297,797 shares, ending with 6,720,389 shares worth $454.84 million. Meanwhile, Wellington Management Group LLP reduced its position by 628,558 shares, now holding 5,371,232 shares valued at $363.52 million.

CG Oncology, Inc. Stock Down 19.9%

CG Oncology, Inc. (NasdaqGS:CGON) is trading around $59.55. The company has a market capitalization of approximately $5.25 billion. It currently has no meaningful P/E ratio due to negative earnings per share. The stock's 52-week range is between $23.65 and $75.50, with a 50-day moving average of $64.93 and a 200-day moving average of $51.37. The company maintains a strong liquidity position with a current ratio of 31.30 and a quick ratio of 30.60.

Recent Earnings

In its recent earnings report, CG Oncology posted revenue of $5.07 million, marking a 19.8% increase. However, the company is not yet profitable, with a negative return on equity of -20.79%. Investors will be looking to the next earnings release on August 7, 2026, for further updates on its financial performance.

Analysts Set New Price Targets

Analysts remain optimistic about CG Oncology's prospects. On May 14, 2026, Truist Securities reiterated a 'buy' rating with a price target of $82. JP Morgan and RBC Capital also maintained 'buy' ratings, setting targets at $96 and $81, respectively. The consensus among 14 analysts is a 'buy' recommendation with a mean price target of $90.29.

About CG Oncology

CG Oncology, Inc. is a biotechnology company based in Dallas, Texas, focused on developing treatments for bladder cancer. Led by CEO Arthur Kuan, the company is advancing its proprietary oncolytic immunotherapy, cretostimogene grenadenorepvec, through various clinical trials. With a team of 142 employees, CG Oncology aims to address the unmet needs of patients with high-risk bladder cancer.

Bottom Line

James Mulay's recent purchase of CG Oncology shares highlights ongoing insider interest in the company. While the firm continues to develop its cancer treatments, investors track its stock performance and institutional moves closely. As a reminder, insider transactions are reported after they occur and reflect past activity.